tiprankstipranks
Advertisement
Advertisement
Climb Bio initiated with a Buy at Guggenheim
PremiumThe FlyClimb Bio initiated with a Buy at Guggenheim
6d ago
Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential
Premium
Ratings
Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential
6d ago
Climb Bio Reports Positive Early-Stage Data for CLYM116
Premium
Company Announcements
Climb Bio Reports Positive Early-Stage Data for CLYM116
9d ago
Climb Bio price target raised to $21 from $12 at Baird
PremiumThe FlyClimb Bio price target raised to $21 from $12 at Baird
1M ago
Climb Bio price target raised to $19 from $8 at BTIG
Premium
The Fly
Climb Bio price target raised to $19 from $8 at BTIG
1M ago
Climb Bio Highlights Budoprutug Progress at R&D Spotlight
Premium
Company Announcements
Climb Bio Highlights Budoprutug Progress at R&D Spotlight
1M ago
Climb Bio to sell 9.481M shares at $9.50 in private placement
PremiumThe FlyClimb Bio to sell 9.481M shares at $9.50 in private placement
2M ago
Climb Bio price target raised to $18 from $10 at Oppenheimer
Premium
The Fly
Climb Bio price target raised to $18 from $10 at Oppenheimer
2M ago
Climb Bio initiated with an Outperform at Mizuho
Premium
The Fly
Climb Bio initiated with an Outperform at Mizuho
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100